China FDA Launches Major Enforcement Campaign; Official Cautions Rainy Days Ahead
This article was originally published in The Gold Sheet
If a widening anti-bribery investigation, a new drug cost survey and looming pricing reform is not enough, China FDA just launched its first major campaign to root out violations in pharmaceutical manufacturing and distribution. Industry needs to get ready for rainy days, an official cautioned.
You may also be interested in...
BEIJING - A deputy director of China's State FDA is under investigation by the Communist Party's top anti-corruption commission, which could have broad ramifications for the drug agency's daily operations
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.